This bill proposes to amend the Public Health Service Act to modify the definition and treatment of certain biologics. Its primary purpose is to ensure that a biologic is not designated as a biological product solely due to the inclusion of a protein that serves as a clinically inactive component . By clarifying this regulatory distinction, the legislation aims to prevent unintended classifications that could impact the approval and availability of these substances. The amendment specifically targets Section 351(i)(1) of the Act, which defines "biological product," and includes a minor technical correction to the existing text.